Date published: 2026-5-7

1-800-457-3801

SCBT Portrait Logo
Seach Input

PC-PLD2 Inhibitors

Phosphatidylcholine-specific phospholipase D2 (PC-PLD2) is an enzyme that plays a pivotal role in the metabolism of phosphatidylcholine, catalyzing the hydrolysis of this major membrane phospholipid to produce phosphatidic acid (PA) and choline. This reaction is critical for various cellular processes, including membrane trafficking, signal transduction, and the regulation of cell proliferation and survival. PC-PLD2's activity is involved in the modulation of intracellular signaling pathways and the formation of lipid second messengers, thereby influencing cellular responses to external stimuli. The enzyme's function is tightly regulated within the cell, and its activity is essential for maintaining cellular homeostasis and facilitating dynamic changes in membrane architecture, which are crucial for processes such as vesicle formation and exocytosis. The inhibition of PC-PLD2 involves a range of mechanisms that directly or indirectly affect its enzymatic activity, thereby impacting the production of PA and subsequent signaling events. One primary mode of inhibition is the alteration of PC-PLD2's interaction with its substrates or cofactors, which can be achieved through the binding of specific inhibitors that block the enzyme's active site or interfere with its allosteric sites. Additionally, modifications in the lipid composition of cellular membranes can influence PC-PLD2 activity by altering the availability of its substrate, phosphatidylcholine, or by changing the physicochemical properties of the membrane, which can affect enzyme localization and function. Post-translational modifications of PC-PLD2, such as phosphorylation or ubiquitination, also play a role in regulating its activity by modifying enzyme stability, subcellular localization, or interaction with other proteins. These inhibitory mechanisms are crucial for controlling the activity of PC-PLD2 under various physiological conditions, ensuring that the production of PA and the activation of downstream signaling pathways are appropriately modulated in response to cellular needs and environmental cues.

Items 11 to 16 of 16 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

Wortmannin can indirectly inhibit PC-PLD2 by targeting PI3K and disrupting signaling pathways that activate PC-PLD2, resulting in reduced PC-PLD2 activity.

Rottlerin

82-08-6sc-3550
sc-3550B
sc-3550A
sc-3550C
sc-3550D
sc-3550E
10 mg
25 mg
50 mg
1 g
5 g
20 g
$84.00
$166.00
$302.00
$2091.00
$5212.00
$16657.00
51
(2)

Rottlerin inhibits PC-PLD2 through its action on protein kinase C delta (PKCδ), which can lead to reduced phosphorylation and activation of PC-PLD2.

Genistein

446-72-0sc-3515
sc-3515A
sc-3515B
sc-3515C
sc-3515D
sc-3515E
sc-3515F
100 mg
500 mg
1 g
5 g
10 g
25 g
100 g
$45.00
$164.00
$200.00
$402.00
$575.00
$981.00
$2031.00
46
(1)

Genistein can indirectly inhibit PC-PLD2 by targeting tyrosine kinases, thereby disrupting signaling pathways that activate PC-PLD2, leading to reduced enzymatic activity.

GW 5074

220904-83-6sc-200639
sc-200639A
5 mg
25 mg
$106.00
$417.00
10
(1)

GW5074 inhibits PC-PLD2 through its impact on mitogen-activated protein kinase kinase 1 (MEK1), which can attenuate downstream signaling pathways that activate PC-PLD2.

Tyrphostin B42

133550-30-8sc-3556
5 mg
$26.00
4
(1)

Tyrphostin B42 can indirectly inhibit PC-PLD2 by targeting Janus kinases (JAKs), interfering with signaling pathways that activate PC-PLD2 and subsequently reducing its enzymatic activity.

CGP 57380

522629-08-9sc-202993
5 mg
$172.00
6
(1)

CGP 57380 inhibits PC-PLD2 indirectly through its action on p38 mitogen-activated protein kinase (MAPK), which can attenuate signaling pathways that activate PC-PLD2.